The use of recombinant adeno-associated viral vectors (rAAVs) as gene transfer tools has
increased dramatically during the past several years, establishing AAV as the vector of …

Potential applications and impact of the adeno-associated virus (AAV) as a gene transfer
vector have expanded rapidly in the last decade. Recent advances in the production of high …

Recombinant adeno-associated virus (rAAV) holds promise for applications in gene therapy.
Advances in clinical studies of rAAV-based gene therapeutics have generated an …

The ability to elicit robust and long-term transgene expression in vivo together with minimal
immunogenicity and little to no toxicity are only a few features that make recombinant adeno …

The adeno-associated virus (AAV) is one of the most promising viral vectors for human gene
therapy. As with any potential therapeutic system, a thorough understanding of it at the in …

Recombinant adeno-associated virus (rAAV) is a prototypical gene therapy vector
characterized by excellent safety profiles, wide host range, and the ability to transduce …

A variety of gene transfer strategies have been developed to treat inherited, degenerative,
and acquired diseases. Among the different vector systems developed so far, recombinant …

Background One of the major limitations to the use of adeno‐associated virus (AAV) vectors
for gene therapy has been the difficulty in producing enough vector to supply a clinical trial …

In recent years, recombinant adenoviral and adeno-associated viral (AAV) vectors have
been exploited in a number of gene delivery approaches. The use of these vectors in clinical …

Recombinant adeno-associated virus (rAAV) vectors are unique among the vector classes
currently available for human gene therapy in that they are based upon a class of viruses …